CSBR · Champions Oncology, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EPS - basic non-GAAP | $0.05 | first quarter of fiscal 2027 | — |
GAAP → non-GAAP reconciliationGAAP EPS – basic, GAAP -$0.03
+$0.06 Effect of stock-based compensation on EPS
+$0.02 Effect of depreciation and amortization on EPS
+$0 Effect of loss on equipment disposal on EPS
+$0 Effect of other expense (income), net on EPS
+$0 Effect of provision for tax on EPS
= Adjusted EPS - basic $0.05
|
|||
| Oncology services margin non-GAAP | 51% | first quarter of fiscal 2027 | — |
| Oncology services profit non-GAAP | 7.7M | first quarter of fiscal 2027 | — |
GAAP → non-GAAP reconciliationGAAP Loss from operations - GAAP -$409K
+$8.11M Research and Development, Sales and Marketing, General and Administrative, and Loss on disposal of equipment
= Oncology services profit $7.7M
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CSBR
this stock
Champions Oncology, Inc.
|
$70.98M | -26.2% | +4.4% | — | 0.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.64B | +13.7% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.46B | +1.2% | +20.8% | 19.4 | 2.5% |
|
ARGX
Argenx SE
|
$61.22B | +17.1% | — | — | 2.0% |
|
MRNA
Moderna, Inc.
|
$57.48B | +388.2% | +4.3% | — | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CSBR | -3.4% | +0.4% | -13.0% | +2.0% | -26.2% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -2.3% | +2.1% | -30.8% | +2.4% | -38.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.